|View printer-friendly version|
|Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC|
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170403005244/en/
(Graphic: Business Wire)
“We are very excited and grateful to receive this substantial
The donation includes information linked to cancer therapies and cancer
subtyping to help clinical researchers identify relevant information
associated with tumor variants gathered from publications and drug
labels. The 8,000 associations cover more than 3,500 unique variants
extracted from close to 700 scientific publications. It includes 74
drugs associated with 100 cancer types that have been collected over 5
years by a team of scientists. The standards employed for variant
curation are similar to those recently published by the
The donated interpretations, with evidence linked directly to their
peer-reviewed source publications, will help clinical research
laboratories engage in precision oncology. These variant associations
are available within BaseSpace
Variant Interpreter (Beta), for use in aiding in interpreting the
significance of individuals’ genetic variants.
Consistent with draft guidance documents released by the FDA on
“This extensive data set will expand our shared genomic knowledge and enable researchers to design personalized therapeutics which aids in advancing genomics into healthcare,” said Sanjay Chikarmane, Senior Vice President and General Manager at Illumina. “The donation to CIViC and ClinVar represents our commitment to help researchers access and share the secure health data information they need to transform healthcare.”
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
The CIViC project is an ecosystem of curators, moderators and other stakeholders that aims to facilitate a collaborative ecosystem of research scientists, clinical scientists, and patient advocates dedicated to creating an accurate and relevant database of clinical interpretations of cancer variants. To learn more, visit https://civic.genome.wustl.edu.
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.